Souza Reynaldo José Sant Anna Pereira de, Mattedi Adriana Prest, Rezende Marcelo Lacerda, Corrêa Marcelo de Paula, Duarte Etiene Marques
Fundação SobecCan, Hospital do Câncer de Ribeirão Preto, SP, Brazil.
An Bras Dermatol. 2009 Jul;84(3):237-43. doi: 10.1590/s0365-05962009000300004.
The purpose of this study was to estimate the direct cost of diagnosing and treating melanoma disease in Sao Paulo (Brazil) between the years 2000 and 2007.
The project Clinical Practice Guidelines in Oncology was used, adapted to the proceedings of SOBECCan Foundation. The estimated costs were based on the values of the medical treatment paid by the Brazilian National Health System (SUS) and private healthcare insurance companies (PHIC) in 2007.
The total cost was estimated in R$33,012,725.1 (SUS) and R$76,133,662.8 (PHIC). Stages 0, I and II comprised about 4.2% (SUS) and 1.3% (PHIC) of the total cost; stages III and IV amounted to 95.8% and 98.7% of the total cost, respectively.
The diagnosis of malignant melanoma in its initial stages reduces treatment costs generating considerable savings of resources for both National Health System and private healthcare insurance companies.
本研究旨在估算2000年至2007年间在巴西圣保罗诊断和治疗黑色素瘤疾病的直接成本。
采用肿瘤临床实践指南项目，并根据SOBECCan基金会的程序进行了调整。估算成本基于2007年巴西国家卫生系统（SUS）和私人医疗保险（PHIC）支付的医疗费用。
总成本估计为33,012,725.1雷亚尔（SUS）和76,133,662.8雷亚尔（PHIC）。0期、I期和II期约占总成本的4.2%（SUS）和1.3%（PHIC）；III期和IV期分别占总成本的95.7%和98.7%。
早期诊断恶性黑色素瘤可降低治疗成本，为国家卫生系统和私人医疗保险节省大量资源。
